| abstract |
Novel polypetides, designated RTD, which are capable of binding Apo-2 ligand are provided. RTD are receptors for the tumor necrosis factor (TNF), belonging to the family of trail - receptors. They are inhibitors of APO2L- induced apoptosis. They act as decoy receptors, lacking an intracellular signalling death domain. Compositions including RTD chimeras, nucleic acid encoding RTD, and antibodies to RTD are also provided. |